Advertisement · 728 × 90
#
Hashtag
#DrugCombination
Advertisement · 728 × 90
Preview
Drug Combination Boosted Lifespan of Mice by 73%, But Only For One Sex What's going on?

Drug Combination Boosted Lifespan of Mice by 73%, But Only For One Sex #Science #HealthandMedicine #GeneticsandGenomics #LifespanResearch #SexDifferences #DrugCombination

0 1 0 0
Preview
Existing Drugs Combine To Fight World’s Most Common Liver Disease Drug repurposing offers a promising and cost-effective strategy for developing new treatments. Metabolic dysfunction-associated steatotic liver disease is now recognized as the most widespread liver disorder...

Existing Drugs Combine To Fight World’s Most Common Liver Disease #Science #HealthandMedicine #InfectiousDiseases #LiverDisease #PublicHealth #DrugCombination

1 0 0 0

9/12 Friede's immune system produced antibodies that recognize common features across these toxins. When researchers isolated two specific antibodies and paired them with varespladib (which inhibits tissue-destroying enzymes), they found a winning combination.
#ImmuneSystem #DrugCombination

0 0 1 0
Post image

🧠💊 New paper out! We highlight how computational network models can guide Drug Combination Development—from discovery to regulatory approval. Excited to share our insights!

📖 Funded by @ffg.bsky.social (911422, 915133)
#DrugDiscovery #SystemsPharmacology #DrugCombos #AIinBiotech #drugcombination

1 0 1 0
Preview
BeiGene's $150M Deal with CSPC Zhongqi: A Bold Move to Compete with Amgen in Cancer Drug Combinations BeiGene is making a significant move in the oncology space with a $150 million deal to license SYH2039, a promising MAT2A inhibitor from fellow Chinese company CSPC Zhongqi Pharmaceutical Technology. ...

www.linkedin.com/pulse/beigen...

BeiGene's $150M Deal with CSPC Zhongqi: A Bold Move to Compete with Amgen in Cancer Drug Combinations

kstrategyand.com/pharma-news

#BeiGene #CSPC #CancerResearch #Oncology #PRMT5 #DrugCombination #InnovationInHealthcare #Humanteconomy #Humantec #KStrategyand

0 0 0 0